The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Molecular Subtyping in Breast Cancer

Massimo Cristofanilli, MD
Published Online: 4:54 PM, Thu December 12, 2013
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.

Clinical Pearls

  • ASCO and CAP are trying to better define patients who may benefit from treatment with targeted therapies
  • The current method of detecting HER2 overexpression/amplification may miss a portion of patients; molecular subtyping is a more accurate way to identify these patients
  • A different molecular profiling signature should be offered to patients who are defined by current guidelines as 'borderline'

<<< Back to the conference page



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.